10 Stocks Lighting Up Market Ahead of Christmas

8. Palisade Bio Inc. (NASDAQ:PALI)

Palisade extended its winning streak to a fourth straight day on Wednesday, jumping 5.26 percent to close at $2.20 apiece as investors loaded portfolios ahead of the results of its clinical trial for its treatment of fibrostenotic Crohn’s disease (FSCD).

The company is targeting to present the topline results of its Phase 1b study of PALI-2108 in the first quarter of 2026, with the Investigational New Drug submission expected in the first half of next year.

The first phase enrolled approximately 6 to 12 patients with FSCD, and was designed to evaluate the efficacy of PALI-2108 over a 14-day treatment period.

Results aside, the rally in Palisade Bio Inc. (NASDAQ:PALI) can also be attributed to some window-dressing activities—a practice among institutional investors where they tweak their portfolios before reporting periods, typically done quarterly and annually, by loading up on well-performing stocks and trimming those that underperform, to perform a stronger portfolio for clients.

Year-to-date, Palisade Bio Inc.’s (NASDAQ:PALI) shares were up by 33.33 percent.

Palisade Bio Inc. (NASDAQ:PALI) is a clinical-stage biopharmaceutical company advancing a next generation of once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases.